An expanded universe of cancer targetsWilliam C. Hahn, Jitong Cai, Jesse S. Boehm et al.|Cell|2021Cited by 221
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunityMeng‐Ju Wu, Nabeel Bardeesy, Hiroshi Kondo et al.|Science|2024Cited by 87
DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional ReprogrammingIlaria Gritti, Nabeel Bardeesy, Jinkai Wan et al.|Cancer Discovery|2024Cited by 14
Abstract 606: Targeting the immune checkpoint PTPN2 with ABBV-CLS-484 inflames the tumor microenvironment and unleashes potent CD8+ T cell immunityArvin Iracheta‐Vellve, Robert T. Manguso, Hakimeh Ebrahimi-Nik et al.|Cancer Research|2022Cited by 8
Abstract ND06: ABBV-CLS-484: An active site PTPN2/N1 inhibitor that augments the immune response and sensitizes tumors to immune-mediated killingChristina K. Baumgartner, Philip R. Kym, Marcia N. Paddock et al.|Cancer Research|2022Cited by 7